“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
|Videos|August 1, 2017
First-Line Treatment of Metastatic Renal Cell Carcinoma
Author(s)Neeraj Agarwal, MD
This video reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for interleukin-2.
Advertisement
In this video, Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for treatment with high-dose interleukin-2.
Agarwal spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5